Warning! GuruFocus detected
1 Severe warning sign
with OTLK.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Outlook Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US68235M1053
Compare
Compare
Traded in other countries / regions
OTLK.USA41O.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2016-05-13Description
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | -2.96 | |||||
| Debt-to-Equity | -0.62 | |||||
| Debt-to-EBITDA | 3.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 17 | |||||
| 3-Year EPS without NRI Growth Rate | 16 | |||||
| 3-Year FCF Growth Rate | 19.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.24 | |||||
| 9-Day RSI | 31.91 | |||||
| 14-Day RSI | 34.51 | |||||
| 3-1 Month Momentum % | -34.38 | |||||
| 6-1 Month Momentum % | -71.89 | |||||
| 12-1 Month Momentum % | -84.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.32 | |||||
| Quick Ratio | 0.26 | |||||
| Cash Ratio | 0.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39.4 | |||||
| Shareholder Yield % | -166.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -134.8 | |||||
| ROIC % | -221.86 | |||||
| 3-Year ROIIC % | -69.84 | |||||
| ROC (Joel Greenblatt) % | 773.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 6.71 | |||||
| EV-to-EBITDA | 6.63 | |||||
| EV-to-Forward-Revenue | 7.6 | |||||
| EV-to-FCF | -0.96 | |||||
| Earnings Yield (Greenblatt) % | 14.9 | |||||
| FCF Yield % | -173.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OTLK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Outlook Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -7.42 | ||
| Beta | -0.21 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.22 | ||
| Volatility % | 73.19 | ||
| 14-Day RSI | 34.51 | ||
| 14-Day ATR ($) | 0.126249 | ||
| 20-Day SMA ($) | 1.41425 | ||
| 12-1 Month Momentum % | -84.56 | ||
| 52-Week Range ($) | 0.87 - 9.98 | ||
| Shares Outstanding (Mil) | 32.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Outlook Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Outlook Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Outlook Therapeutics Inc Frequently Asked Questions
What is Outlook Therapeutics Inc(OTLK)'s stock price today?
The current price of OTLK is $1.20. The 52 week high of OTLK is $9.98 and 52 week low is $0.87.
When is next earnings date of Outlook Therapeutics Inc(OTLK)?
The next earnings date of Outlook Therapeutics Inc(OTLK) is 2025-05-16 Est..
Does Outlook Therapeutics Inc(OTLK) pay dividends? If so, how much?
Outlook Therapeutics Inc(OTLK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers